0.00
+0.0004(+200.00%)
Currency In USD
Address
142 North Cedros Avenue
Solana Beach, CA 92075
United States of America
Phone
858 925 8215
Website
Sector
Healthcare
Industry
Biotechnology
Employees
14
First IPO Date
March 01, 2021
| Name | Title | Pay | Year Born |
| Mr. Craig R. Jalbert CIRA | Chief Executive Officer, President, Treasurer &Secretary, and Director | 0 | 1962 |
| Dr. Davide Ruggero Ph.D. | Co-Founder and Member of Clinical & Scientific Advisory Board | 0 | N/A |
| Dr. Kevan M. Shokat Ph.D. | Co-Founder and Member of Clinical & Scientific Advisory Board | 0 | N/A |
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.